People

Sean Khozin is published by Atropos Health as life sciences advisory board member. Senior Partner, Life Sciences & Healthcare at Braven; Founder of Phyusion. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket. Existing separately sourced biography: Sean Khozin, MD, MPH, is a physician, oncologist and data scientist who serves as CEO of the CEO Roundtable on Cancer and Project Data Sphere. He joined Weave Bio’s Strategic Advisory Board inJuly2026. Previously a founding member of the FDA Oncology Center of Excellence, he established its INFORMED data-science incubator and worked at CancerLinQ and Johnson & Johnson.

Stewart Hen is managing partner at Serrado Capital and a member of Weave Bio’s Strategic Advisory Board, appointed inMarch2026. The company identifies him as an investment and capital-markets adviser. His advisory role does not by itself establish an individual investment.

Tala Fakhouri, PhD, MPH, is chief AI and regulatory strategy officer at Parexel and joined Weave Bio’s Strategic Advisory Board inJuly2026. She previously led AI policy and data science work in the FDA Office of Medical Policy, including guidance on AI in drug development.

Ray Zhou co-founded Affinity, the AI relationship-intelligence and CRM company, after studying computer science at Stanford. He stepped down from the co-CEO role when Ken Fine became CEO in May2024 and remains a co-founder and board member. Ray Zhou is published by Neo as Affinity co-Founder. This is a publicly listed external mentoring or applicant-interviewing affiliation, not an assertion of employment by Neo or a personal investment.

Shubham Goel co-founded Affinity, the AI relationship-intelligence and CRM company, after studying computer science at Stanford. He stepped down from the co-CEO role when Ken Fine became CEO in May2024 and remains a co-founder and board member.

Co-founder and General Partner of Standard Capital. Former CTO of imeem and co-founder and CEO of App.net. Joined Stripe in 2014 and previously served as Staff Engineer and early Head of Security, building security controls, datacenter and edge infrastructure. Rochester Institute of Technology Information Technology graduate.

Ari Caroline is co-founder and Chief Strategy Officer of Weave Bio, confirmed in its current leadership directory. He was CEO when the company announced its USD10M seed financing inMay2024; the current title reflects a subsequent leadership change.

Shefali Roy is listed in Affinity Africa’s current public directory as Advisor, Risk and compliance. This published affiliation does not establish a personal cash investment.

Nilan Peiris is listed in Affinity Africa’s current public directory as Advisor, Product and growth. This published affiliation does not establish a personal cash investment.

Brandon Rice is co-founder and CEO of Weave Bio, which develops AI for regulatory content and knowledge management in drug development. The company’s current leadership directory and2025SeriesAannouncement identify him as CEO. Earlier investor material identified him as Chief Product Officer; the current company title takes precedence.

Ivanna Palmiero is listed in Affinity Africa’s current public directory as Advisor, Media and communications. This published affiliation does not establish a personal cash investment.

Christine Gorman serves as Operations at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Domenic Lippa is listed in Affinity Africa’s current public directory as Advisor, Design and branding. This published affiliation does not establish a personal cash investment.

Yura Hwang serves as Operations at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Marcus Fedder is listed in Affinity Africa’s current public directory as Advisor, Development and impact. This published affiliation does not establish a personal cash investment.

Brendan Baker serves as General Counsel at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Ismail Douiri is listed in Affinity Africa’s current public directory as Advisor, Banking and regulation. This published affiliation does not establish a personal cash investment.

Niama El Bassunie is listed in Affinity Africa’s current public directory as Advisor, Operations and strategy. This published affiliation does not establish a personal cash investment.

Alyssa Rowell serves as Finance at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Mary Boakye is listed in Affinity Africa’s current public directory as Advisor, Legal and advisory. This published affiliation does not establish a personal cash investment.

Denis Laloy serves as CFO at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Colin Walsh founded US digital bank Varo in 2015 and served as its CEO for a decade, according to Affinity Africa. He serves on Affinity Africa’s global strategic board. He is distinct from the life-sciences investor at Goldman Sachs with the same name.

Cameron Llewellyn serves as Investor at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Isaac Ick serves as Investor at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Andrew Daawin is listed in Affinity Africa’s current public directory as Chief Technology Officer.

Dotun Adejare serves as Investor at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Steven Bastian is listed in Affinity Africa’s current public directory as Group CFO.

David Wehrs serves as Partner & COO at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Michael Annor is listed in Affinity Africa’s current public directory as Head of Product.

Peter Nelson serves as Partner at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Jan Petzel is listed in Affinity Africa’s current public directory as Board Member (Ghana); Board Member (Global). This published affiliation does not establish a personal cash investment.

Rory Carmichael serves as Partner at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Tarek Mouganie is founder and group CEO of Affinity Africa and serves on its Ghana and global boards. A Ghanaian entrepreneur, he previously worked in academia at Cambridge and in financial investing at Man Group. He is distinct from the founders of US CRM company Affinity.

Ziyaad Khayrattee serves as Partner at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics.

Dorothy Mensah is listed in Affinity Africa’s current public directory as Board Member (Ghana). This published affiliation does not establish a personal cash investment.

Sol Bier serves as Founding Partner at Factorial Funds, a venture firm investing across AI, silicon, infrastructure and robotics. He founded the firm in 2021 and previously worked on the early team at Cruise Automation.

Dario Bianchi is listed in Affinity Africa’s current public directory as Board Member (Ghana); Board Member (Global). This published affiliation does not establish a personal cash investment.

Doug Lacey is listed in Affinity Africa’s current public directory as Chairman (Ghana); Chairman (Global).

Doreen Baffoe is listed in Affinity Africa’s current public directory as Head of People and Culture.

Gifty Ossei Boating is listed in Affinity Africa’s current public directory as Chief Risk Officer.

Abdul-Jaleel Hussein is listed in Affinity Africa’s current public directory as Chief Executive Officer; Board Member (Ghana). This published affiliation does not establish a personal cash investment.

Maya Yamaguchi is listed in Affinity CRM’s current public directory as Customer Success Manager, Mid Market I.

Aaron Hu is listed in Affinity CRM’s current public directory as Senior Technical Support Engineer.

Nicole Lynd is listed in Affinity CRM’s current public directory as Executive Business Partner.

Grant Storey is listed in Affinity CRM’s current public directory as Senior Software Engineer II.

Pam Holmberg is listed in Affinity CRM’s current public directory as Chief People Officer.

Puneet Mulchandani is listed in Affinity CRM’s current public directory as SVP Product.

Lindsay Bayuk is listed in Affinity CRM’s current public directory as Chief Marketing Officer.

Jesse Lott is listed in Affinity CRM’s current public directory as Chief Customer Officer.

Sean Kearns is listed in Affinity CRM’s current public directory as Chief Revenue Officer.

Rebecca Campbell is listed in Affinity CRM’s current public directory as Chief Technology Officer.

Ken Fine is listed in Affinity CRM’s current public directory as Chief Executive Officer.

Alex Gasner is a director of Proxima Bio, formerly VantAI Holdings, as disclosed in the company’s June 2026 SEC Form D amendment. A directorship does not establish a separate personal investment.

Raymond Deshaies serves on the Scientific Advisory Board of Proxima Bio, the AI and structural-proteomics company formerly known as VantAI. The company identifies their background as: CO-CONCEIVER OF THE PROTAC NATIONAL ACADEMY OF SCIENCES MEMBER FORMER SVP OF GLOBAL RESEARCH AT AMGEN.

Lyn Jones serves on the Scientific Advisory Board of Proxima Bio, the AI and structural-proteomics company formerly known as VantAI. The company identifies their background as: PRINCIPAL INVESTIGATOR AT DANA-FARBER CANCER INSTITUTE FORMER HEAD OF CHEMICAL BIOLOGY AT PFIZER.

Juri Rappsilber serves on the Scientific Advisory Board of Proxima Bio, the AI and structural-proteomics company formerly known as VantAI. The company identifies their background as: XLMS PIONEER FULL PROFESSOR AND CHAIR OF BIOANALYTICS AT TECHNISCHE UNIVERSITÄT BERLIN.

Bradley L. Pentelute serves on the Scientific Advisory Board of Proxima Bio, the AI and structural-proteomics company formerly known as VantAI. The company identifies their background as: PROFESSOR OF CHEMISTRY AT MIT AND ASSOCIATE MEMBER BROAD INSTITUTE OF HARVARD AND MIT.

Ian Churcher serves on the Scientific Advisory Board of Proxima Bio, the AI and structural-proteomics company formerly known as VantAI. The company identifies their background as: PROTEIN DEGRADATION PIONEER EX-CSO AMPHISTA SVP DRUG DEVELOPMENT BENEVOLENT.

Bruno Correia serves on the Scientific Advisory Board of Proxima Bio, the AI and structural-proteomics company formerly known as VantAI. The company identifies their background as: ASSOCIATE PROFESSOR AND LEADER OF THE LABORATORY OF PROTEIN DESIGN & IMMUNOENGINEERING AT EPFL.

Philippe Schwaller serves on the Scientific Advisory Board of Proxima Bio, the AI and structural-proteomics company formerly known as VantAI. The company identifies their background as: ASSISTANT PROFESSOR HEAD OF LABORATORY OF ARTIFICIAL CHEMICAL INTELLIGENCE (LIAC) AT EPFL.

Morteza Sadat is AI SCIENTIST III at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Dan Marquess is INTERIM CHIEF SCIENTIFIC OFFICER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Yugandhar Kumar is PROTEOMICS SCIENTIST at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Xinyi Shao is LAB SCIENTIST at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Sven Gutjahr is AI SCIENTIST INTERN at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Michael Lazear is SENIOR DIRECTOR/HEAD OF PLATFORM at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Julian Cremer is SENIOR AI SCIENTIST at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Josh Southern is SENIOR AI SCIENTIST at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Inese Steinberga is SENIOR EXECUTIVE ASSISTANT at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Filippos Kottakis is ASSOCIATE DIRECTOR BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Dom Vigil is VP/HEAD OF BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Daniele Grattarola is HEAD OF MACHINE LEARNING at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Rohit Advani is SENIOR RESEARCH ASSOCIATE at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Charlotte Kelley is PRINCIPAL BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Taarak Shah is TARGET STRATEGY INTERN at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Calliste Skouras is STRATEGY & OPERATIONS ASSOCIATE at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Jack Kabrich is DIRECTOR STRATEGY & OPERATIONS at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Aditi Palkar is ASSOCIATE DIRECTOR PROJECT MANAGER/ALLIANCE MANAGEMENT at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Patrick Kunzmann is STAFF SCIENTIFIC SWE at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Giulia Crocioni is SENIOR SCIENTIFIC SOFTWARE ENGINEER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Thomas Duignan is PRINCIPAL SOFTWARE ENGINEER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Kai Wohlfahrt is SENIOR PRINCIPAL SOFTWARE ENGINEER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Danny Kovtun is VP ENGINEERING at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Haichan Niu is SENIOR LEAD SCIENTIST MEDICINAL CHEMISTRY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Chalada Suebsuwong is DIRECTOR MEDICINAL CHEMISTRY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Jerome Eberhardt is COMPUTATIONAL CHEMIST III at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Manav Kumar is SENIOR COMPUTATIONAL CHEMIST at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Adam Green is PRINCIPAL COMPUTATIONAL CHEMISTRY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Dwight McGee is PRINCIPAL SCIENTIST COMPUTATIONAL CHEMISTRY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Vladas Oleinikovas is SENIOR DIRECTOR COMPUTATIONAL CHEMISTRY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Si-Han Chen is SENIOR DIRECTOR HEAD OF COMPUTATIONAL CHEMISTRY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Dana Felker is COMPUTATIONAL BIOLOGIST II at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Milan Avila is COMPUTATIONAL BIOLOGIST III at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Graham Holt is COMPUTATIONAL BIOLOGIST III at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Douglas Wu is SENIOR PRINCIPAL COMPUTATIONAL BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Adam Borne is SENIOR PRINCIPAL COMPUTATIONAL BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Thomas Gilgenast is SENIOR PRINCIPAL/DIRECTOR COMPUTATIONAL BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Yusuf Adeshina is SENIOR PRINCIPAL/DIRECTOR COMPUTATIONAL BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Alexander Goncearenco is SENIOR DIRECTOR COMPUTATIONAL BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Cristina Di Genua is SENIOR DIRECTOR BIOLOGY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Thomas Castiglione is AI SCIENTIST III at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Clemens Isert is AI SCIENTIST III at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Michael Pun is AI SCIENTIST III at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Mehmet Akdel is STAFF AI SCIENTIST at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Meiling Thompson is CHIEF OF STAFF at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Adriana Altomonte is HEAD OF PEOPLE at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Liz Brady is LAB OPS MANAGER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Qijia Yu is PROTEOMICS SCIENTIST at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Cathy Marulli is PROTEOMICS PLATFORM LEAD at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Sam Gerritz is VP HEAD OF CHEMISTRY at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Matthias Grass is VP R&D STRATEGY AND OPERATIONS at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Jeremy Sokolove is INTERIM CHIEF MEDICAL OFFICER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Jack McFarland is CHIEF FINANCIAL OFFICER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Zachary Kanter is CHIEF BUSINESS OFFICER at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Brian A. McCarthy is a senior adviser to Patient Square Capital and a retired healthcare investment banker. He previously led healthcare banking at Bank of America, JPMorgan and Lehman Brothers. He serves on Patterson and Premier boards and advises healthcare analytics business Intus Care.

Colin Shannon is a senior adviser to Patient Square Capital and chair of Clinigen’s board. He previously chaired and led PRA Health Sciences and held international clinical-operations and finance leadership roles at Pharmaceutical Product Development.

Jim Mazzo is a senior adviser to Patient Square Capital and executive chair of Neurotech, which develops therapies for chronic eye diseases. His earlier leadership includes Allergan, Advanced Medical Optics, Abbott, AcuFocus and Carl Zeiss Meditec’s ophthalmic business. Jim Mazzo is a current Iantrek board member; the company identifies his Neurotech Pharmaceuticals executive-chairman affiliation. He is distinct from Feldan board chairman DavidJ.Mazzo.

Stuart Kurlander is a senior adviser to Patient Square Capital. He previously co-led Latham & Watkins’ global healthcare and life-sciences and Israel practices, building the law firm’s healthcare practice in Washington, DC.

Stephen Oesterle is a senior adviser to Patient Square Capital. He previously led medicine and technology at Medtronic and directed interventional cardiology programs at Stanford and Massachusetts General Hospital. He has also advised venture and private-equity investors in healthcare. Stephen Oesterle is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Baxter, Paragon 28, Medicine & Technology, Medtronic. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments. Between 2002 and 2015, Stephen was a member of Medtronic’s Executive Committee, serving as Senior Vice President for Medicine and Technology. In this role, he contributed to the company’s business development, operating plans and long-term strategies. In addition, Stephen had corporate oversight of Medtronic’s technology R&D, developing and leading collaborative relationships with technical universities, high tech corporations and medical device start-ups. Prior to this, Stephen served as Associate Professor of Medicine at the Harvard University Medical School and as Director of Invasive Cardiology Services at Massachusetts General Hospital, Boston. As a teacher and innovator in the field of cardiac catheterization, he also developed and directed interventional cardiology programmes at Good Samaritan Hospital, Los Angeles, as well as at the universities of Georgetown and Stanford. Stephen is independent director on several public and private boards in the USA, Switzerland, Germany and China. Stephen serves on a wide range of boards, including Baxter International (NYSE), Peijia Medical (Shanghai) Paragon 28 (NYSE), Private equity backed SHL Medical AG (Zürich) and  CeramTec (Germany) and venture backed Alcyone Therapeutics and Anuncia.

Mark Blumling is an executive in residence at Patient Square Capital. He founded and led clinical-research business Headlands Research and genomics company Genos, and co-founded Hyperion Therapeutics. He also advises Goldman Sachs Growth Equity and teaches at Stanford Law School.

Connie Liu serves as Receptionist at Patient Square Capital. Earlier experience includes a General Manager at Club Pilates.

Claire Hammer serves as Receptionist at Patient Square Capital. Earlier experience includes the Sales Manager at Buck Mason Women in New York City.

Lisa Vu serves as Administrative Assistant at Patient Square Capital. Earlier experience includes a Senior Administrative Assistant at San Francisco Bay University.

Joyci Man serves as Administrative Assistant at Patient Square Capital. Earlier experience includes a receptionist at Rosewood Sand Hill.

Samina Qadri serves as Administrative Assistant at Patient Square Capital. Earlier experience includes a Client Coordination Analyst at ICONIQ Capital.

Erica Sun serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Administrative Assistant at Moelis & Company.

Natasha Perez serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant to the Managing Partner at Holland & Knight.

Gina Poole serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant to various senior leaders at Euclid Mortgage.

Jenn Ostergard serves as Executive Assistant at Patient Square Capital. Earlier experience includes executive Assistant to the KeyBanc Capital Markets Technology Group.

Kristy Yip serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant at KKR supporting various members of KKR Capstone.

Jocelyn Morales serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant at Point72 Private Investments.

Ellie Dawson serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant in private wealth.

Stanley Lieuw serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Associate in Investor Relations at Nassau Global Credit.

Aleeza Ojascastro serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant and Operations Specialist at Catalyst Family Office.

Dominika Füstös serves as Executive Assistant at Patient Square Capital. Earlier experience includes the Office Manager for the Chief Executive Officer at Dubai International Financial Centre Authority.

Krhistine Jones serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant at several technology companies, including Amazon, Microsoft, and Meta.

Iris Phee serves as Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant at Digital Realty.

Marileny Acevedo serves as Senior Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant at Braidwell.

Misha Wainwright serves as Senior Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant to various senior executives at KKR.

Paula Mo serves as Senior Executive Assistant at Patient Square Capital. Earlier experience includes an Executive Assistant at Golden Gate Capital.

Kelvin Tsang serves as Technology Support Specialist at Patient Square Capital. Earlier experience includes a consultant at Sculptor Capital Management.

Hailey Ni serves as Senior Tax Accountant at Patient Square Capital. Earlier experience includes a Fund Accountant at Olive Partners Management.

Emily Yeung serves as Senior Tax Accountant at Patient Square Capital. Earlier experience includes a Tax Senior at Catalyst Family Office.

Alexandra Yampolsky serves as Senior Finance Professional at Patient Square Capital. Earlier experience includes at Gryphon Investors as a Finance Assistant and AP Specialist, supporting the management company.

Kyle Dahlstrom serves as Head of Facilities at Patient Square Capital. Earlier experience includes mr Dahlstrom held facilities and operations roles at TPG Capital and Boston Consulting Group.

Paige Brinskele serves as Human Capital and Administrative Manager at Patient Square Capital. Earlier experience includes in Human Resources at Macias Gini & O’Connell.

Joanne Young serves as Administration Executive at Patient Square Capital. Earlier experience includes an Executive Assistant at TPG Capital.

Rebecca Marty serves as Administration Executive at Patient Square Capital. Earlier experience includes vice President of Conferences and Events for the Technology Investment Banking practice at KeyBanc Capital Markets.

Dalila Leon serves as Compliance Associate at Patient Square Capital. Earlier experience includes a Compliance Associate at Andreessen Horowitz.

Stephanie Ching serves as Accounting (Management Company) and Accounts Payable Manager at Patient Square Capital. Earlier experience includes an accounting consultant at Meta (Accounting Operations Manager) and Intercom (Interim GL Manager).

Trevor Thompson serves as Accounting and Investor Services Manager at Patient Square Capital. Earlier experience includes a Senior Accountant at KKR.

Devon Presutti serves as Corporate Affairs Specialist at Patient Square Capital. Earlier experience includes an Associate on the Marketing and Communications team at Oaktree Capital Management.

Shiyu Dong serves as Senior Tax Manager at Patient Square Capital. Earlier experience includes a Tax Manager at Andersen Tax.

Rachel Kuff serves as Accounting Manager at Patient Square Capital. Earlier experience includes a Senior Manager in the Accounting Advisory practice at CFGI.

Jave Balajadia serves as Senior Accounting Manager at Patient Square Capital. Earlier experience includes the Asset Management practice at KPMG.

Leo Chan serves as Technology Specialist at Patient Square Capital. Earlier experience includes mr Chan provided high-level technical and executive support at Coffer Group, LLC, Greylock Partners, Las Vegas Sands, Oak Hill Capital Management, and Gap, Inc.

Rishi Raj serves as Cloud Infrastructure Engineer at Patient Square Capital. Earlier experience includes at Deloitte and Northern Trust.

Dmitriy Markelov serves as Infrastructure Engineer at Patient Square Capital. Earlier experience includes vice President of Infrastructure Engineering at Mizuho Financial Group.

Susan Mauldin serves as Corporate Systems Engineer at Patient Square Capital. Earlier experience includes ms Mauldin held various senior systems engineering roles at Informatica.

Thomas Buck serves as Associate Data Engineer at Patient Square Capital. Earlier experience includes a Data Science Consultant at West Monroe Partners.

Anna Dickson serves as Associate Data Engineer at Patient Square Capital. Earlier experience includes a Data Engineer at Osmo, an early-stage startup at the intersection of technology and human health.

Tyler Hook serves as Lead Data Engineer at Patient Square Capital. Earlier experience includes at Coatue.

Brett Battaglia-Szyjka serves as Lead Data Engineer at Patient Square Capital. Earlier experience includes mr Battaglia-Szyjka delivered cloud and data engineering solutions at Starwood Capital, Meridian Capital, Willis Towers Watson, and IQVIA.

Leanne Zhao serves as Fund Controller at Patient Square Capital. Earlier experience includes a Senior Fund Manager at Riverwood Capital.

Tia Vang serves as Controller at Patient Square Capital. Earlier experience includes an Assistant Controller at Bertram Capital.

Aniket Mehta serves as Vice President, Finance and Operations at Patient Square Capital. Earlier experience includes a Senior Vice President at TresVista, a global advisory firm serving private equity and investment banking clients.

Jeff Dorenkott serves as Vice President, Finance (Management Company) at Patient Square Capital. Earlier experience includes vice President of Private Equity Finance & Accounting at Ares Management.

Mel Estrada serves as Director, Finance and Accounting at Patient Square Capital. Earlier experience includes a Senior Manager in Asset Management Practice at KPMG and at BDO USA LLP.

Rauf Osipov serves as Senior Technology Manager at Patient Square Capital. Earlier experience includes vice President of Technology at KKR.

Angela Choksi serves as Capital Associate at Patient Square Capital. Earlier experience includes an Institutional Client Solutions Analyst in the Private Equity group at Blackstone.

Mohammed Odeh serves as Relationship Manager at Patient Square Capital. Earlier experience includes a Senior Manager on the Business Development team at the Dubai International Financial Centre.

Matt Lee serves as Fund Partnerships Operations Lead at Patient Square Capital. Earlier experience includes a Client Strategy Associate at Angel Island Capital, a former specialty finance portfolio company of Golden Gate Capital.

Jonathan O'Hare serves as Vice President, Capital Analytics at Patient Square Capital. Earlier experience includes with 5C Investment Partners on financial planning and forecasting, and before that served as Vice President of FP&A at Consello.

Olivia Wang serves as Vice President, Capital at Patient Square Capital. Earlier experience includes an Associate at Hellman & Friedman.

Ronak Bhagia serves as Research Associate at Patient Square Capital. Earlier experience includes a Consultant at ClearView Healthcare Partners.

Ruoyu Gu serves as Research Associate at Patient Square Capital. Earlier experience includes a Consultant at Boston Consulting Group.

Bara Badwan serves as Lead Data Scientist at Patient Square Capital. Earlier experience includes at the intersection of biotechnology, predictive analytics, and investment intelligence.

Nelson Lamkin serves as Associate at Patient Square Capital. Earlier experience includes an Investment Banking Analyst in the health care services group at Guggenheim Securities.

Aviral Asthana serves as Associate at Patient Square Capital. Earlier experience includes an Investment Banking Analyst in the health care services group at Guggenheim Securities.

Thomas Heagy serves as Associate at Patient Square Capital. Earlier experience includes an Associate in the Health Care Financial Advisory Group at Lazard.

Matthew Hom serves as Associate at Patient Square Capital. Earlier experience includes an Associate in the Investment Banking Division at Leerink Partners.

Fielden Baker serves as Associate at Patient Square Capital. Earlier experience includes an Analyst in the health care group of the Investment Banking Division at Moelis & Company.

Tara Krumenacker serves as Associate at Patient Square Capital. Earlier experience includes in the health care group of the Investment Banking Division at J.P.

Roshini Balasubramanian serves as Associate at Patient Square Capital. Earlier experience includes in the health care group of the Investment Banking Division at Barclays.

Usman Baig serves as Associate at Patient Square Capital. Earlier experience includes an Associate at Brookfield Asset Management.

Sophia Lee serves as Associate Director at Patient Square Capital. Earlier experience includes a Consultant at Boston Consulting Group.

Aki Dhadda serves as Associate Director at Patient Square Capital. Earlier experience includes a Consultant at Boston Consulting Group.

Amy Liang serves as Analyst at Patient Square Capital.

Andrew Li serves as Associate Director at Patient Square Capital. Earlier experience includes at The Global Fund under the Office of the Executive Director.

William Li serves as Associate Director at Patient Square Capital. Earlier experience includes a Consultant at Bain & Company.

Rachel Densley serves as Associate Director at Patient Square Capital. Earlier experience includes at Oxeon Venture Studio.

Griffin Hyde serves as Director, Head of Responsibility at Patient Square Capital. Earlier experience includes a Vice President at Malk Partners.

Joel Bateman serves as Director at Patient Square Capital. Earlier experience includes a Senior Associate at Boston Consulting Group.

Sorochi Van Sickle serves as Vice President, EMPIRIC Institute at Patient Square Capital. Earlier experience includes on the Houston Medical Monitoring Project, an HIV surveillance project funded by The Centers for Disease Control and Prevention.

Paul O'Brien serves as Director at Patient Square Capital. Earlier experience includes an Associate Director on the M&A team at BridgeBio Pharma.

Will Oprea serves as Executive Principal at Patient Square Capital. Earlier experience includes a Director on the Park Hill Group Private Equity team at PJT Partners and has worked alongside Patient Square since the launch of Patient.

Alexander Moran serves as Research Lead at Patient Square Capital. Earlier experience includes a Project Leader at Boston Consulting Group.

Oliver Smith serves as Research Lead at Patient Square Capital. Earlier experience includes a Project Leader in the health care practice at Boston Consulting Group, leading strategy engagements for biopharma, medical technology, and health care provision clients.

Kaitlin Sandor serves as Research Lead at Patient Square Capital. Earlier experience includes on the corporate development and strategy team at insitro, a company leveraging machine learning and high-throughput biology for drug discovery and development.

Udai Singh serves as Vice President at Patient Square Capital. Earlier experience includes an Associate at Marlin Equity Partners.

Jason Grosz serves as Vice President at Patient Square Capital. Earlier experience includes a Principal on the life sciences team at B Capital.

Milly Wang serves as Vice President at Patient Square Capital. Earlier experience includes a Vice President at 65 Equity Partners.

Joan Thompson serves as Vice President, Capital Markets at Patient Square Capital. Earlier experience includes a Vice President on the Health Care Investment Team at Thomas H.

Kyle Fan serves as Vice President at Patient Square Capital. Earlier experience includes a Director at Altas Partners.

Philip Groenwegen serves as Vice President at Patient Square Capital. Earlier experience includes an Associate on the health care team at TPG Capital.

Hannah Carlino serves as Vice President at Patient Square Capital. Earlier experience includes an Associate at Golden Gate Capital.

Benjamin Strauss serves as Vice President at Patient Square Capital. Earlier experience includes a Vice President at Marathon Asset Management, and prior to that, a consultant at McKinsey & Company.

Catherine Soler serves as Director at Patient Square Capital. Earlier experience includes ms Soler built two ESG programs at private equity and growth investing firms, Vista Equity Partners and SoftBank’s Vision Fund.

Sam Saini serves as Head of Technology at Patient Square Capital. Earlier experience includes nearly 20 years at KKR and most recently served as a Director in the Technology, Data, and Engineering group.

Ryan Peabody serves as Data Analytics Lead at Patient Square Capital. Earlier experience includes a Vice President at Starwood Capital Group, overseeing the firm’s Data Science team and focusing on the development of quantitatively driven strategies for capital.

Zachary Strasser serves as Real-World Data Analytics Lead at Patient Square Capital. Earlier experience includes a faculty member at Massachusetts General Hospital (MGH) and Harvard Medical School.

Katherine Ackerman serves as Deputy General Counsel at Patient Square Capital. Earlier experience includes a Partner at Kirkland & Ellis.

Nate Seaman serves as Executive Director at Patient Square Capital. Earlier experience includes a Senior Vice President at Envision Healthcare.

Vladislava Chalei serves as Senior Research Lead at Patient Square Capital. Earlier experience includes director of Strategy and Corporate Development at BioNTech.

Derek Lu serves as Senior Research Lead at Patient Square Capital. Earlier experience includes a Principal in the health care practice at Boston Consulting Group, advising clients on strategic and operational topics within medical technologies, devices, and pharmaceuticals.

Katie Cumnock serves as Senior Research Lead at Patient Square Capital. Earlier experience includes a Project Leader at Boston Consulting Group.

Ryan Gallagher serves as Executive Research Lead at Patient Square Capital. Earlier experience includes a Principal in the health care practice at Boston Consulting Group.

Richard Stec serves as Executive Director at Patient Square Capital. Earlier experience includes the global technology leader in Deloitte’s Strategic Acquisition Services group.

Rebecca Rooney serves as Managing Director, Head of Product Management at Patient Square Capital. Earlier experience includes a Founding Partner, Chief Operating Officer, and Chief Compliance Officer at Consello, an advisory and private equity firm.

Carolyn Drayer-Greenwalt serves as Managing Director, Chief Compliance Officer at Patient Square Capital. Earlier experience includes the Chief Compliance Officer at Genstar Capital.

Kelsey Hilbrich serves as Principal at Patient Square Capital. Earlier experience includes a Principal at Flexpoint Ford.

Patrick Martin serves as Principal at Patient Square Capital. Earlier experience includes a Director at GTCR.

Vasundhara Bhargava serves as Principal at Patient Square Capital. Earlier experience includes a Vice President at Golden Gate Capital.

Kiran Jinsi serves as Managing Director, Capital Markets at Patient Square Capital. Earlier experience includes a Director in the Leveraged Finance division at Barclays.

Ang Sun leads AI transformation at Patient Square Capital as a managing director in Transformation and Growth. His earlier work includes enterprise AI leadership at Humana and digital innovation at Roivant Sciences. He holds a computer-science PhD from New York University.

Nikhilesh Chand serves as Head of Patient Square Public Opportunities at Patient Square Capital. Earlier experience includes the Chief Strategy Officer in Residence at BridgeBio Pharma.

Ellie Humphrey serves as Managing Director at Patient Square Capital. Earlier experience includes ms Humphrey served in senior leadership roles at various global health care companies, most recently at Zimmer Biomet as an SVP and the Chief.

Tom Stanton serves as Managing Director at Patient Square Capital. Earlier experience includes a Managing Director and the Head of Family Wealth at The Carlyle Group.

Ken Michalzuk serves as Managing Director at Patient Square Capital. Earlier experience includes 11 years at KKR.

Kelvin A. Baggett serves as Senior Managing Director, Head of Patient Impact and Chair of the EMPIRIC Institute at Patient Square Capital. Earlier experience includes the Executive Vice President & Chief Impact Officer at McKesson, a Fortune 10 company.

Chris Wade serves as Partner, Chief Financial Officer at Patient Square Capital. Earlier experience includes a combined 20 years at Ares Management (where he served as Chief Accounting Officer for Private Equity and Opportunistic Credit) and at KKR Credit.

Bhavna V. Katkar serves as Partner; Head of Human Capital, Enterprise Solutions, and Corporate Affairs at Patient Square Capital. Earlier experience includes the Head of Strategic Initiatives and Human Capital at private investment firms Veritas Capital and BC Partners.

Kaveh Samie is Patient Square Capital’s Middle East chairman and CEO, a partner and head of international fund partnerships. His earlier leadership roles covered the Middle East and North Africa at Neuberger Berman and KKR.

Jason Ridloff is a capital markets partner at Patient Square Capital. He previously led healthcare direct lending, restructuring and opportunistic investments at Carlyle, and managed direct-lending and distressed strategies at BlackRock. His earlier career includes KKR and Credit Suisse.

Emily Janvey serves as Partner, Co-Head of Royalty and Structured Solutions at Patient Square Capital. Earlier experience includes a Managing Director at Carlyle / Abingworth.

Russ Chong is a partner and co-head of royalty and structured solutions at Patient Square Capital. His earlier career includes leading Citigroup’s North American equity capital markets and healthcare investment banking businesses. He holds law and business degrees from McGill.

David Katz serves as Partner at Patient Square Capital. Earlier experience includes an advisor and member of the Investment Committee at The Pritzker Organization.

Justin Sabet-Peyman is a partner and deal team leader at Patient Square Capital. He previously invested with KKR’s Americas healthcare team and helped develop Mubadala’s direct-investment platform, following consulting at McKinsey. He studied electrical engineering at Stanford.

Jake Cabala serves as Partner, Head of Fund Partnerships at Patient Square Capital. Earlier experience includes the Head of Capital Formation at Golden Gate Capital.

Adam Fliss serves as Founding Partner; Head of Strategy, Capital, Legal, and Government Affairs at Patient Square Capital. Earlier experience includes general Counsel of TPG Capital.

Karr Narula serves as Founding Partner, Head of Transformation and Growth at Patient Square Capital. Earlier experience includes 13 years at KKR.

Katy Wu is Office Administrator at Ajax Health and studied Romance Languages at the University of Missouri.

Erin Arnold is an Ajax Health Executive Assistant with experience supporting music organizations, technology executives and philanthropic growth initiatives.

Melody Erfani supports Ajax Health as Executive Assistant. Earlier roles include marketing at Silver Linings Technology and executive support at Aisling Capital; she also works in theatre.

Calvin Wei is Controller at Ajax Health, with prior venture fund accounting and reporting experience at Venrock and asset management audit work at PwC.

Seattle Hickey is an Ajax Health Analyst who previously evaluated healthcare and life sciences growth buyouts at 3 Boomerang Capital. She studied history and science at Harvard.

Kayla Heiny is Senior Associate at Ajax Health. Her experience covers engineering and surgical intelligence product management at Stryker and NuVasive, with biomedical engineering, business and public health training.

Caroline Ferner is Senior Associate at Ajax Health. She previously consulted on biotechnology strategy at ClearView Healthcare Partners and studied neuroscience at Harvard.

Luke Rohlen is Vice President at Ajax Health and an observer on the XII Medical board. Earlier work spans Cordis project management, Cortex business development and investment banking at DBO Partners.

Neil Zimmerman is VP of Engineering at Ajax Health, with medical device research and therapy development experience. His earlier work includes Half Moon Medical and mitral valve technologies at Twelve.

Giselle Campos leads human resources at Ajax Health and XII Medical. She previously built people and talent functions at Orca Bio and supported technology company teams.

Andrew Churchill is co-founder and CTO of Weave, the San Francisco engineering intelligence company at weaveos.com. He was Causal's first employee, building its spreadsheet interface, access controls and AI onboarding engine. He studied computer science and mathematics at MIT.

Bill Steiner oversees compliance at Ajax Health Management Company, LLC. His concurrent ICONIQ Capital legal role covers investment adviser compliance and other regulatory matters.

Adam Cohen is co-founder and CEO of Weave, the San Francisco engineering intelligence company at weaveos.com. He previously led sales and customer success at Causal and has a background in operations and sales, including performance measurement for teams of more than 100 people. He and Andrew Churchill met at Causal before starting Weave.

Carla Jung is Entrepreneur in Residence at Ajax Health and commercial chief of Maverix Medical. Her background includes cardiovascular product launches and senior sales leadership at Medtronic.

Joe Koblish is Operating Partner at Ajax Health with more than three decades of medical device engineering experience. He helped invent the EPIX technology acquired by Medtronic and previously led strategy at Cortex.

Shane Kreidel is Partner and SVP Legal at Ajax Health. He previously advised venture and growth equity transactions for life sciences companies at Cooley and trained in law at Harvard.

Casey Dougan leads operations as Partner and SVP at Ajax Health. His career includes operating leadership at Kedalion Therapeutics and life sciences consulting at McKinsey.

Cason Kynes is an Ajax Health Partner and formerly served as operating chief of Cortex before its acquisition. His background includes Harvard legal training and enterprise software work at Oracle.

Aftab Kherani is Managing Partner at Ajax Health and a physician trained in cardiac surgery. He previously invested at Aisling Capital and continues as its Operating Partner. Ajax lists board service at Cortica, Endovascular Engineering, Puzzle Medical and XII Medical.

Doug Koo is Managing Partner at Ajax Health, with executive and consulting experience across medical devices and healthcare. His work includes finance leadership at Cordis-X and Maverix Medical and board service at Cortica and Puzzle Medical.

Duke Rohlen founded Ajax Health in 2017 and serves as CEO and Managing Partner. He previously built and led medical device companies including EPIX Therapeutics, Spirox and CV Ingenuity and leads Ajax operating platforms.

Bianca Iulia Simion is named as .lumen’s Chief Marketing Officer and press contact in its October 2025 PABLO robotics grant announcement. The role is qualified to that company statement; a verified individual portrait was not found.

Marina Denisa Dascăl conducts clinical and public health research at .lumen. The current company page identifies Marina as Principal Investigator; her university-hosted CV identifies work as a research psychologist at Dotlumen since July 2022. She co-authored research on usability of AI-based independent pedestrian navigation for blind people.

Tassos (Anastasios) Natsakis leads feedback research at .lumen and studies machine interfaces for people with visual impairments. His university CV lists dotLumen research since December 2022, alongside robotics and biomechanics teaching and research at the Technical University of Cluj-Napoca. He holds a biomechanics PhD from KU Leuven.

Daniel Elliott is a clinical adviser to UroMems and a Mayo Clinic urologist in Rochester, Minnesota. His research includes urinary incontinence, artificial urinary sphincters, female urology and pelvic reconstruction. His training included a neurourology fellowship at Baylor College of Medicine.

Ty Erickson is a clinical adviser to UroMems and a urogynecologist at Rosemark Women’s Care Specialists in Idaho Falls. His background includes obstetrics, gynecology, pelvic surgery and medical leadership. He trained at Brigham Young University, the University of Nevada School of Medicine and the University of Colorado.

Emmanuel Chartier-Kastler is a clinical adviser to UroMems and a professor and chief of urology at Pitié-Salpêtrière Hospital and Sorbonne University in Paris. His clinical and research work includes functional urology, urinary incontinence and neurourology.

Riccardo Pessina is a UroMems board observer and an Investment Officer at the European Innovation Council Fund. He previously worked in project and corporate finance at the European Investment Bank. He holds a master’s in accounting and finance from Bocconi University.

Jocelyn Jackson is a UroMems board observer and Partner and Senior Vice President of Finance at Ajax Health. Her prior finance roles include Symic Bio, TauTona Group, CV Ingenuity and Deloitte. She holds a bachelor’s degree from the University of San Diego.

Prior to joining Samsung Ventures, Hyungkoo spent nine years at Myriad Partners, where he led venture creation, early-stage investment and business development initiatives across the biotech and healthcare sectors. Before that, he worked in the Strategy Group at Deloitte Consulting. He holds an M.S. from the KAIST Graduate School of Bio Innovation Management and a B.S. from the University of Virginia.

Prior to joining Samsung Ventures, Sunjoo worked in the laboratory of William Hahn, MD, Ph.D. at Dana Farber Cancer Institute and Broad Institute of Harvard and MIT, studying p300/CBP dependency in cancer. While she was a Ph.D. candidate, she worked as a venture capital fellow covering the biotech sector at Longitude Capital Management. Prior to starting her doctoral work, she worked at Memorial Sloan Kettering Cancer Center as a researcher, studying the molecular mechanism of aberrant cell division in cancer. As an undergraduate, she trained in the laboratory of Gregg Semenza MD PhD, (2019 Nobel Prize in Physiology or Medicine) at the Johns Hopkins University School of Medicine, studying the role of HIFs in breast cancer metastasis. Sunjoo holds a Ph.D. in Biological & Biomedical sciences from Harvard University and a B.S. in Molecular and Cellular Biology from the Johns Hopkins University.

Prior to joining Samsung Ventures in 2026, he worked at CJ CheilJedang's Bio Research Institute for 7 years as a senior researcher, where he focused on genetic engineering and cultivation process development. He also has experience in process development for the commercialization of biofoundry technology. He received his B.S. in Chemistry and his Ph.D. in Chemical and Biomolecular Engineering, both from KAIST.

Prior to joining the Life Science team, Kyung Im worked in corporate strategy, financial planning, and fund management at Samsung Ventures, where she developed a strong financial and strategic perspective on investment activities. Her experience includes developing a broad understanding of capital structure and investment economics. Building on this background, she has a strong interest in investment opportunities across the life sciences sector where technological innovation translates into long-term business value. Before joining Samsung Ventures, she managed corporate taxation and accounting at Hanwha Ocean. Kyung Im holds an MBA from Columbia Business School, and a B.A. in Economics from Ewha Womans University.

Prior to joining Samsung Ventures in 2017, he worked at a venture capital firm for 2 years and EPC company for 4 years. His investment domain experience has spanned across vetrical AI in financial industry (e.g., dataOps, legal, etc) and built environmental technologies (ESS, renewable energy, etc). He holds MBA, and M.S/B.S in architectural engineering.

She joined Samsung Ventures in 2022 and specializes in investments in the health tech, medical devices, and lifestyle platforms.

Helena's focus areas include food tech, digital healthcare, and platform agnostic in EM market. Prior to joining Samsung Ventures, Helena worked with Samsung Securities Research covered consumer staples, and platform sectors in Greater China market. Helena holds an EMBA degree from Qinghua University and a BA in Law from Hanyang University.

Chris is an Investment Director where she manages strategic investments for Ag/Food/Beauty-tech and security-tech opportunities that create synergies within Samsung's ecosystem. Previously, she worked on strategic investments for Samsung Electronics' Device Experience division (mobile, TV, home appliances), covering companies across consumer technology, gaming, and immersive audio sectors. Before joining venture capital, she spent eight years at LG Electronics as an HVAC product strategist for Asia-Pacific markets, developing go-to-market strategies across Southeast Asia and India. She holds an MBA from Hong Kong University of Science and Technology and a BS in Mechanical Engineering from Yonsei University.

Before joining Samsung Venture Investment, he worked for fashion research team and new business planning group in Samsung C&T Fashion Group, building insights on the domestic and international fashion markets, including brands, distribution, and consumption trends. Based on these experiences, he intends to help Samsung's fashion business grow further by discovering rising brands with both commercial value and creativity in the future. He graduated from Seoul National University with a bachelor's degree in aesthetics.

Before joining Samsung Ventures, Teal worked as a software engineer at Toss, the first Korean fintech unicorn, for 7 years, leading key data intelligence projects. He also previously served as a business consultant at Kearney, and his expertise covers fintech, AI, blockchain, and platform businesses. Teal holds both Bachelor’s and Master’s degrees in Industrial & Systems Engineering from KAIST, and earned an additional Master’s degree in Industrial Engineering from TU Berlin in Germany.

Taewoo Jeon is currently leading an investment Team4, focusing on insurtech, AI, and financial services. Certified actuary with 12+ years of experience in insurance risk management at Samsung Life, specializing in pricing, underwriting, and reinsurance. He combines deep industry insight with strategic investment expertise to support innovative startups shaping the future of risk and finance.

Before joining Samsung Ventures, Daniel gained experience in both the consulting and tech industries. He started his career as a consultant at Nomura Research Institute. Then, he moved to LINE and contributed to launching its cryptocurrency, LINK (Finschia), and developing its blockchain business as a lead. After working at LINE, he transferred to NAVER’s AI business division, CLOVA, and worked as a business strategy manager. Uiseok earned his MBA from the University of California, Berkeley Haas School of Business, and his B.S. in Industrial Engineering from Hanyang University.

Before joining Samsung Ventures, Daehwan worked as a data scientist across marketing, partnerships, and product domains. He kicked off his career at Samsung Electronics, using data to help drive digital transformation. Then at Meta, he partnered with global telcos to get more people connected to faster internet and helped build AI tools to automate ad creation. Most recently at Coupang, he led a team of data scientists, elevating the customer experience within its flagship shopping app. Daehwan holds a BA in Mathematics from Rice University and an MA in Economics from Columbia University.

Prior to joining Samsung Ventures, she began her career as a battery development engineer at Samsung Electronics, later transitioning to the Open Innovation team. She then worked at Hanwha Aerospace’s Open Innovation team, focusing on deep tech CVC investments, and subsequently led business development at the Korea office of Solid Power, a U.S.-based solid-state electrolyte company. At Samsung Ventures, she focuses on deep tech investments with a particular emphasis on the AI sector. She holds a BS and PhD in Chemistry from the University of Maryland, with a specialization in battery technologies.

Before joining Samsung Venture Investment, Youngoh worked as an AI researcher at a software company, leading B2B and B2G AI projects. He later served as the product lead for GPU?based AI infrastructure solutions at KT, where he drove product strategy and commercialization. His current areas of focus include enterprise AI, AI infrastructure (GPU/cloud), and next?generation technologies such as agentic AI. He holds a Bachelor’s degree in Systems Management Engineering and a Master’s degree in Artificial Intelligence from Sungkyunkwan University.

Prior to joining Samsung Ventures, he led new business sourcing and development within the CTO Division at LG Innotek. Since joining Samsung Ventures in 2024, he worked in Market Intelligence, responsible for analyzing global venture trends and scouting new technologies. Currently, he focuses on identifying promising investment opportunities in the AI and Display sectors as a member of Investment Team 3. He holds an M.S. in Chemical Engineering from the University of Florida

Prior to joining Samsung ventures, Saemi started her career as a staff engineer at Samsung Research, the advanced R&D hub of Samsung Electronics, where her research scope focused on identifying new future growth areas and developing them into the products and services. Particularly, she was actively involved in the area of environmental sensing and control, mainly air-related work. Saemi received her B.S., M.S., and Ph.D. in material science and engineering from Seoul National University. During the course, she extended her research boundary as an exchange researcher at Monash University, Australia.

She joined Samsung Ventures in 2022 and specializes in deep tech investments. Previously, she worked at ZER01NE of Hyundai Motor Group, where she led startup acceleration programs. MJ Kim holds a Bachelor’s degree in Business Economics from the University of California, Irvine (UC Irvine).

Jongwook Kim is currently leading the ICT Team. He began his career at Samsung Electronics in 2009 as an engineer, designing automated production lines for components such as mobile phone cameras. He holds an MBA from the China Europe International Business School (CEIBS) and both a Master’s and Bachelor’s degree in Mechanical Engineering from Yonsei University.

JS joined Samsung Ventures in 2017 and currently leads strategic investments in the energy sector. Over the years, he has built a strong track record of investments across a broad range of companies and industries. With a background in both Venture Capital and engineering, JS brings a unique blend of technical and financial insights. JS holds an M.S. degree in Organic Chemistry and a B.S. in Chemistry.

Prior to joining Samsung Venture Investment, Byeongcheol worked at the Korea Institute of Energy Technology Evaluation and Planning(KETEP) for over four years, where he played a key role in overseeing the overall energy R&D budget and aligning projects with national policies. He also served as a project manager in the smart grid field, evaluating and managing R&D projects. Based on his experience, he specializes in energy technology evaluation, power systems, and sustainable innovation. Byeongcheol received a B.S. in Electrical Engineering from Pusan National University and an M.S. in Electrical Engineering from Pohang University of Science and Technology.

Before joining Samsung Ventures, he worked at a petrochemical company. He initially worked as a researcher developing catalysts for petrochemical processes and later moved to the research planning team, where he was responsible for new business development and open innovation. He mainly focused on sustainable technologies such as hydrogen, CCUS, and recycling. He holds a Bachelor's and a Ph.D. in Chemical Engineering from Korea University.

SunMin has about 10 years of experience in power generation industry at energy solution company Hanwha Energy before joining Samsung Venture Investment. Through her career in both engineering and management, she has experienced a diverse range of projects across a wide range of energy sector ? Coal, Photovoltaic, LNG, CCUS and others based on ESG. She mainly involved in strategy, joint venture establishment, project management and financing, government relations, and commercial plant operation/engineering. She holds a Bachelor’s degree in Chemical engineering from Rutgers University, New Jersey US.

Charlie Lee leads on investments in the Energy sector ? including clean energy, smart grids that integrate information and communication technologies into traditional power systems, and industrial automation ? as well as in the Lifestyle sector, covering fashion, food and beverage, agriculture, marketing technology, and consumer goods. He earned a Bachelor’s degree in Electrical Engineering from Korea University and an MBA from the Owen Graduate School of Management at Vanderbilt University in the United States.

Before joining Samsung Ventures, Jase began his career in venture capital at Quad Ventures. Prior to that, he worked as a research engineer at Hyundai Mobis, where he developed ADAS (Advanced Driver Assistance System) logic for two mass-production vehicle models. He holds both a B.S. and M.S. in Mechanical Engineering from the Georgia Institute of Technology.

Rohan joined Samsung Ventures in 2025 and is responsible for investments in the Indian deep tech ecosystem. He joined Samsung in 2018 as part of the Global Strategy Group, and spent over 7 years across different roles in HQ and India, driving strategic projects and partnerships for the Mobile, TV, Digital Appliance and IoT businesses. Previously, Rohan also worked in PwC's Deals Strategy team, advising companies and investment funds in the tech and consumer space. He holds an MBA from INSEAD, a Master's Degree in Finance from IE Business School, and a Bachelor's Degree in Electronics and Communication Engineering.

Snehal Deshpande joined Samsung Ventures in July 2017 brings over 25 years of experience. Snehal initially joined Samsung R&D in 2005 and has undertaken variety of roles in SW Development, Technology & Product planning, Open Innovation, and Technology Incubation & IP Management.. Prior to Samsung, Snehal had engineering experience in Defence Industry.

He joined Samsung Ventures Japan in 2025. Naoya began his career as a researcher for Tohoku University as an assistant professor. Then, he joined Device Solutions R&D Japan in Samsung Electronics as a member of technology intelligence, mainly investigating advanced technology trends with global TI members of Samsung Advanced Institute of Technology. He has a deep understanding of semiconductor technology, especially TCAD simulations, such as density functional theory, molecular dynamics, and computational fluid dynamics. Based on his strong technology background having over 7 years, he contributes to find promising local start-ups and connect them to Samsung. He earned Ph.D. degree in engineering from Tohoku University. He also has a global experience through many international research projects, staying in France, USA, and Netherlands for several months each.

He joined Samsung Ventures in 2023, beginning his career as a venture capitalist at SBI Holdings before moving to the headquarters of SBI Investment in Japan. He has invested in a wide range of Japanese startups in fields such as AI technology, IT services, blockchain, and entertainment. In 2022, he achieved exits totaling over 10 billion yen and was recognized as one of the Top 5 most influential venture capitalists in Japan on Forbes Japan’s “Midas List,” becoming the first Korean ever to receive this honor. Having lived in Japan for over 15 years, he leverages his deep understanding of Japanese culture and business trends to serve as a bridge between Samsung and Japanese startups at Samsung Ventures Japan.

Vanessa is currently focusing on robotics, biotech, new energy, display material, and other deep tech areas. in Greater China region. She joined Samsung Ventures in 2015. Prior to Samsung Ventures, Vanessa worked in Samsung’s Global Strategy Group on strategy development projects for various business units. Vanessa is a CFA charterholder. She holds an MBA from INSEAD and completed her BBA at School of Economics and Management in Tsinghua University in China.

Chris’s journey at Samsung starts in 2015 from Samsung Global Strategy Group, where he worked on a wide variety of technology related projects for Samsung Mobile, Samsung VD, and Samsung Fire and Marine Insurance. After GSG, Chris left Korea shortly to first serve as the Chief of Staff at Lenovo and then he joined JD.com’s mobile advertising department to help manage JD’s ~$3 bn+ advertising P&L. Chris recently joined Samsung Ventures in 2019 and his focuses are technology & information services, AIoT, and FinTech. Chris holds MBA from Columbia Business School. He is a Fellow of Society of Actuaries and also passed all three CFA exams (not chart holder).

Jaeyoung is Vice President and Head of Asia at Samsung Ventures, he is actively looking for investment opportunities across the Asia including Greater China, Japan, India and South East Asia. Prior to joining Samsung Ventures in early 2010, he has worked at Samsung Advanced Institute of Technology(SAIT) as a fuel cell researcher in Korea as well as worked as a R&D Staff at Fuel Cell Lab of Forchungszentrum Juelich, Germany. He grew up in Seoul & Singapore and earned Master in mechanical engineering from Aachen University of Applied Science in Germany, and attended Tongji University in Shanghai, China for the same major prior to Germany.

Marom joined Samsung Ventures in 2024. Before joining, he served as a Venture capitalist in an Israeli early stage Financial VC. Marom started his career as an electrical engineer in a technological unit within the Israeli military, refining his skills as a system engineer and product manager. With an educational background in Electrical Engineering from Bar- Ilan University and an MBA from the Technion.

He joined Samsung Ventures Israel office in 2019 and Patrick is responsible for investments in Fintech, Insuretech, Enterprise SW solutions including cybersecurity and new generation sensor technologies. Prior to joiningSamsung Ventures, he worked at LG Technology Center in Israel as a technology cooperation manager, scouting for Automotive and Service related startups in Israel.

Having joined in 2023, Petros is responsible for identifying strategic deals across Europe, while also supporting portfolio companies in their growth. Petros has a diverse background spanning venture capital, consulting and research. Before joining Samsung, Petros led the London office of Vickers Venture Partners, a global deeptech and lifesciences venture fund investing in disruptive IP-rich start-ups. Prior to that, his career was in strategy consulting and data science, most recently serving as a Senior Data Science consultant at Monitor Deloitte in London. Petros holds a doctorate from the University of Cambridge in the field of Nanophotonics (Physics) and a masters in Physics from the University of Bristol.

He brings 15 years of operational and investment experience to his role. He initially joined Samsung Electronics’s Mobile Business in 2004 as an Engineer and Marketer and spent some time in Management Consulting and Business Development role in various companies.

He joined Samsung Ventures in 2012 and focuses on investments in mobile platform, AI, IoT, digital media & content, and enterprise solution. Prior to joining Samsung Ventures, Thomas worked in Benex investment, a private equity in Korea. Before Benex investment, he worked at SK Telecom in global strategy planning team and investment team. Thomas led deals in the US, China, Vietnam, and Korea mainly focusing on mobile and internet. Before SK Telecom, Thomas worked at a RF repeater system company, MTI Co., Ltd. as a RF, S/W engineer. Thomas also co-founded two start-ups, a social network service website, win520.com in Beijing, China, and an outdoor digital signage company, Intercity Networks in Korea and he was an early member of Chinese mobile device company, Xiaomi. Thomas earned his M.B.A. at the Wharton School and received his B.S. degree in Electrical Engineering from Seoul National University.

Theo joined Samsung Ventures in 2025 and works horizontally across early-stage AI infrastructure and applications. Theo previously worked at McKinsey & Company as a Business Analyst, while working part-time as a Venture Scout for an emerging enterprise AI fund, Carya Venture Partners. Prior to that, Theo was the Co-founder and COO of Lunar, a Web3 services firm that generated $1.5M+ in net income and raised $4.6M+ in cumulative ICO funding. Theo holds a B.A. in Economics and Data Science from the University of California, Berkeley.

Siddharth is a Managing Director at Samsung Ventures, focusing on investments in AI, Robotics and Semiconductors. Siddharth has a decade long experience in technical roles at companies like Apple, Nvidia and Maxim Integrated. Most recently Siddharth worked as a system architect at Apple, where his team was responsible for early stage technology investigations for enhancing the Apple consumer product lines. This included developing the first prototypes for Apple Vision Pro and various features in iphones, MacBook, AirPods etc. Prior to Apple, Siddharth was an ASIC engineer at Maxim Integrated, where he helped build the company’s first smartgrid communication solutions. Siddharth holds an MBA from UC Berkeley, Haas School of Business, an MS in Electrical Engineering from Stanford University and a B-Tech in Electronics Engineering from Indian Institute of Technology.

Rob joined the Samsung Ventures in 2023. He explores broadly across the technology spectrum relevant to Samsung Group, with specific focus areas in energy storage & generation, clean & climate tech, display technologies, and advanced materials applicable many different fields. Prior to joining Samsung Ventures, Rob worked for 11 years in the Open Innovation group supporting the Samsung Advanced Institute of Technology (SAIT), where he developed internal R&D strategy and supported external collaboration activities. He has experience in energy technologies, batteries, quantum computing, and advanced materials. Rob has also served as a volunteer mentor in the startup ecosystem, including for the Creative Destruction Lab and The Engine’s Blueprint program. Rob has a PhD in Chemical Engineering from MIT and a BS in Chemical Engineering from NC State University. Prior to joining Samsung in 2012, he was a postdoctoral researcher at Ghent University in Belgium and worked for Exponent as a technical consultant in their Thermal Sciences practice.

Renee joined Samsung Ventures in 2025. Prior to joining the firm, she worked at Connecticut Innovations, the strategic venture capital arm for the state of Connecticut, where she invested across multiple life science verticals including therapeutics, R&D tools, digital health, and AgTech. During her tenure, she participated in several notable transactions, including the acquisitions of Modifi Bio by Merck and Halda Therapeutics by Johnson & Johnson. Renee earned her Ph.D. in Molecular, Cellular, and Developmental Biology from Yale University and her B.S. in Molecular and Cellular Biology from the University of Connecticut.

Liam joined Samsung Ventures in 2017 and leads investments in Physical AI, an emerging field at the intersection of Robotics, AI, and advanced sensing. Physical AI spans technologies that enable machines to perceive, learn, and act in the physical world ? from humanoid and industrial robots, to embodied AI systems, to novel platforms that combine sensors, actuators, and foundation models for real-world intelligence. Prior to Samsung Ventures, Liam was part of MindMeld (acquired by Cisco), a conversational AI startup pioneering next-generation chat and voice assistants. He previously managed Fortune 500 accounts at Samsung Electronics, where he worked closely with global partners across consumer electronics and enterprise solutions. Liam holds an MBA from UC Berkeley’s Haas School of Business and a bachelor’s degree in Business Administration from Seoul National University.

Ji Hoon runs strategic investments at Samsung Ventures America, working with AI companies in data centers, energy, industrial automation, healthcare, and enterprise SaaS. He has spent several years building expertise in technical evaluation and creating frameworks to assess AI algorithms and their practical applications. His investment approach focuses on finding technologies that address real business problems, especially those with clear paths to adoption in large organizations. He combines his financial market background with technical assessment capabilities, bridging the gap between innovative startups and enterprise customers who can benefit from their solutions. Before entering venture capital, he managed public equities in TMT sectors in one of the hedge funds in New York, and ran technology portfolios at Credit Suisse and Industrial Bank of Korea, where he developed his analytical approach to investments. He earned his MBA from Northwestern University's Kellogg School of Management.

Jihong joined Samsung Ventures in 2012 and focuses on investments in AI, software, services and robotics. Prior to Samsung Ventures, he worked as a research analyst at a hedge fund (SFG), in investment banking (HSBC, JMP), and in management consulting (PwC). He began his career as a software engineer at Lucent Technologies and was an early team member at startups including nDosa and CommASIC (acquired by Freescale). Jihong holds an MBA and a BS in Electrical Engineering & Computer Science from UC Berkeley.

Jaemin Lee is a Vice President and Head of the Life Science Global Strategy Team at Samsung Ventures, where he identifies innovative Life Science companies across the U.S. and Europe. He leverages his extensive expertise to identify and invest in groundbreaking technologies, with a primary focus on areas such as antibody drug conjugates, gene & cell therapy, and AI-driven drug discovery. Prior to joining Samsung Ventures in 2018, he served as a Principal Scientist at Samsung Bioepis from 2014 to 2018, and before that, as a Senior Researcher at both GC Pharma and Hanmi Pharmaceuticals. His educational background includes a Ph.D. candidate in Management of Technology from Korea University, an M.S. in Molecular and Life Science from Pohang University of Science and Technology (POSTECH), and a B.S. in Life and Genetic Engineering from Korea University.

Albert has more than 25 years of experience in venture capital. Prior to Samsung Ventures he was the head of Ericsson Ventures, as well as Managing Director at Investor Growth Capital. He is passionate about new technologies and business ideas, meeting founders, builders, and business leaders. Albert holds a PhD in applied physics from Harvard University and a Diplom in physics from RWTH Aachen.

Prior to joining Samsung Ventures in 2021, She worked at Samsung C&T and ASML as an engineer about 7 years. She has built up the knowledge and experiences in semiconductor field as she cooperated with Samsung Electronics. She received the B.S degree in mechanical engineering from Georgia Institute of Technology.

His tenure at SK hynix, spanning memory semiconductor development, technology strategy, and business strategy, cultivated a unique insight into connecting the entire semiconductor value chain-from a technology's inception to its market strategy. This forms a solid foundation, blending deep R&D knowledge with macroscopic business acumen to multi-dimensionally analyze a technology's potential and forecast its future growth equation. Joining Samsung Ventures in 2022, he now focuses on identifying the 'Next Wave' of innovations poised to lead the next-generation semiconductor industry.

Prior to joining Samsung Ventures in 2025, she worked at LG Chem and Hanwha Corporation as a researcher for 9 years in the IT materials field, where she was responsible for the synthesis of OLED materials and optical components. Based on this experience, she has developed a interest in organic and inorganic materials. She received both her B.S. and M.S. degrees in chemistry from KAIST.

Jinho started his career in Samsung Electronics as a semiconductor process architect in 2013. Then, beyond his engineer career, he was in charge of global tech sensing and new business development in SK inc. materials. Based on various experience in broad semiconductor area, he skilled at building strategic partnerships with startups and corporate unit, driving value creation at the intersection of deep-tech innovation and corporate growth. Jinho received his B.S and M.S degree in Material Science and Engineering from Seoul National University.

Jun is currently working in the Materials & Components Group at Samsung Ventures, where he explores strategic partnerships with innovative companies in the display, battery, and broader materials, components, and equipment sectors. Before joining Samsung Ventures in June 2022, he spent six years as a senior research engineer at LG Display and LG Electronics, focusing on advanced materials and display technologies. He holds both B.S. and Ph.D. degrees in Materials Science and Engineering from Seoul National University.

Prior to joining Samsung Ventures in 2024, he worked at Samsung Electronics as a SoC design and verification engineer and, worked at the Korea Automotive Technology Institute as a senior researcher for automotive semiconductor R&D projects and business developing. Based on his prior experiences, he is interested in semiconductor and artificial intelligence areas which have recently attracted attention for various applications such as Generative AI, LLMs and AI Semiconductors. He received a B.S degree in semiconductor system engineering from SungKyunKwan University and an M.S degree in brain engineering from Korea University.

Prior to joining Samsung Ventures in 2021, She worked at Samsung Electronics and ON semiconductor as an in-house patent attorney of IP legal team for 11 years. She handled IP issues including patent development strategies, and analysis of infringement risks of semiconductor from memory to PMIC. Based on that working experience, she specializes in the semiconductor and related industries. She received the B.S degree in mechanical engineering from Hongik University and holds an MBA degree from Peking University.

Nathan Han is Vice President and Head of the Core Industrial Technology Team at Samsung Ventures. He joined Samsung Ventures in 2014 and currently leads investments related to Semiconductor, Display, Battery, Electronics Parts. Prior to that, he worked at Samsung Electronics from 2001 to 2012 as a process development engineer, specializing in process optimization and failure analysis for display panel manufacturing. From 2012 to 2014, he was part of the planning team at Samsung Display He holds a B.S. in Electronic Engineering and an M.S. in Device Physics.

Wonyoung Yoo is Vice president, Head of division 3 and Life Science team. Wonyoung brings over 25 years of experience across whole value chain for biological medicine development. He joins Samsung ventures from Samsung BioEpis where he was lead for Program management, Corporate planning, Corporate innovation, and Cell development. As a founding member of BioEpis, he served as a principal scientist for Program management and a group leader focusing on Biosimilar development. He previously worked as a scientist developing Biobetter, Artificial skin and IVD (in vitro diagnostics) at Dong-A pharmaceutical. Wonyoung holds Bachelor and Master of science for Biology from Seoul National University. He received his Ph. D. from Sungkyunkwan university in Pharmacology.

A highly accomplished and results-driven investment professional with over 20 years of experience in strategic planning and venture capital investment. Currently serving as Executive Vice President and Head of Investment Division 2 at Samsung Ventures, leading a team focused on identifying and fostering promising startups. Proven ability to analyze market trends, evaluate investment opportunities, and drive successful investment outcomes. Expertise in financial analysis, strategic planning, and venture capital. Holds an MBA from Seoul National University, and a B.S. in Materials Science and Engineering from Korea University..

Sung Hoon Yang currently serves as the Head of Investment Division for the sectors of Semiconductor, Display, Battery, Electronics Parts, and Energy at Samsung Ventures Korea HQ, after serving for 4 years as the Head of US activities in Silicon Valley. Before joining Samsung Ventures, he worked for Samsung Electronics Display Division as an engineer with his expertice from the quantum-mechanics based research on organic materials in his PhD thesis at Seoul National University.

Jonghyuk Lee joined Samsung SDI in 1996 as a Senior Researcher at the Basic Research Laboratory and has since held key leadership positions including Head of the OLED Advanced Technology Team at Samsung Mobile Display and Head of the QD Development Team at Samsung Display. Most recently, he served as Executive Vice President of the Large Display Business Division at Samsung Display, overseeing the QD-OLED business and contributing to the strengthening of the company’s technological competitiveness in the display sector. With deep expertise in IT and electronic components as well as an extensive global network, he is expected to lead Samsung Ventures in identifying promising next-generation technologies and driving the firm’s continued growth and global position as a premier corporate venture capital organization.

Partner at Pinegrove Venture Partners, confirmed by Silicon Valley Bank’s June 2025 State of Enterprise Software webinar. His investing focuses on B2B SaaS and enterprise software. His professional biography refers to Pinegrove Ventures. No personal investment is inferred from public reposts of company fundraising news.

Managing Partner at Pinegrove Venture Partners since his return announced February 23, 2026, helping lead venture fund investments, co-commitments and co-investments. He worked at predecessor SVB Capital from 2007 to 2013, later led global technology fund investing at Five Arrows and previously managed venture and technology buyout investing at ADIA.

Former SVB Capital Managing Partner for Life Science and Healthcare, appointed in August 2020 to develop its life-sciences direct investment practice. The Alexandria 2023 proxy reports a change in occupation by March 2023; she subsequently returned to Silicon Valley Bank. First Citizens Innovation Banking currently identifies her as Head of Relationship Management. Previously served on Pfizer’s venture capital team; trained in bioengineering and biotechnology at the University of Pennsylvania and earned a Wharton MBA.

Vice President at SVB Capital in its 2021 conference biography, responsible for investment research, portfolio construction and manager underwriting for fund-of-funds vehicles. Previously worked at the David and Lucile Packard Foundation and Cambridge Associates. Stanford political science graduate. Historical title; current role requires a current primary source.

Managing Director of SVB Capital in its April 2020 own conference agenda. This profile documents that historical appointment and does not infer current employment from legacy event pages.

President of SVB Capital in primary 2020 and 2021 announcements. This is a historical role; current employment is not established by those records.

Historical managing partner of SVB Capital, confirmed in its 2020 conference agenda. Pinegrove Venture Partners identifies him alongside Aaron Gershenberg and Thorben Hett as a leader of its venture fund investment, co-commitment and co-investment program in February 2026.

Co-founder and historical managing partner of SVB Capital, which he joined in 1999. He developed fund-of-funds and direct investment programs. In February 2026 Pinegrove Venture Partners identifies him as its CEO and Managing Partner. He holds degrees from Wesleyan University and Harvard Kennedy School.

Pierre Mozer is Chief Medical Officer and co-founder of UroMems and a board observer. He is a practicing urologist and Sorbonne University professor whose research spans smart systems, robotics and clinical urology. He completed an information technology doctorate at Joseph-Fourier University and postdoctoral work at Johns Hopkins.

Rinda Sama is a UroMems director with medical-device operations and quality experience. He was formerly Chief Operating Officer at Axonics and previously led operations and quality at Vessix Vascular. He holds a biomedical engineering master’s from USC and an MBA from the University of California, Irvine.

Johannes Fischer is a UroMems director and a life sciences investor at Wellington Partners. Wellington’s current directory lists him as Managing Partner; he joined in 2020 and previously worked in life sciences strategy consulting at L.E.K. He holds biochemistry, biotechnology and medical qualifications from Technical University Munich.

Jérôme Feraud is a UroMems director and Head of the Health Division at Crédit Mutuel Innovation. His prior investing experience includes ACG Management and GO Capital. He holds a master’s in immunology and an executive MBA from IAE Aix.

Jeremy Durack is a UroMems director and Partner and Senior Vice President of Medical Affairs at Ajax Health. He is an interventional radiologist and former Vice-Chair of Radiology at Memorial Sloan Kettering Cancer Center. He trained in psychology and neuroscience at Duke, medicine at Stanford, and radiology and informatics at UCSF.

Philippe Boucheron is a UroMems director and Deputy Chief of Life Sciences Investment at Bpifrance. He co-founded Bioam Funds in 2000, which subsequently became part of Bpifrance through mergers. His background includes BioCapital and ING Barings; he trained in biochemical engineering and holds an INSEAD MBA.

David Beylik is a UroMems director and Partner at Ajax Health. His background includes operating responsibilities at Maverix Medical, corporate law at Latham & Watkins and a clerkship for U.S. Supreme Court Chief Justice John Roberts. He studied at Harvard Law School and the University of Southern California.

Stéphane Lavallée is a co-founder and board member of UroMems. He is a medical robotics entrepreneur whose work includes image-guided surgical robotics, Praxim, eCential Robotics, Orthotaxy and the BizMedTech/MinMaxMedical accelerator. His earlier surgical robot work with Professors Benabid and Cinquin was applied in neurosurgery.

Hamid Lamraoui is CEO and co-founder of UroMems and a member of its board. A biomedical engineer, he has led the development of its implantable mechatronics platform since inception. He earned his engineering degree at Aix-Marseille University and a biomedical engineering doctorate at Grenoble University.

Dan Rose chairs UroMems and is CEO of Endovascular Engineering. He previously led LimFlow through its acquisition by Inari Medical and held leadership roles at Direct Flow Medical, Sequana Medical and Medtronic. He holds degrees from the University of Virginia and an MBA from its Darden School.

Arnie Fishman is a co-founder of AppliedVR. Fellow co-founder David Sackman identifies Fishman, Matthew Stoudt and Josh Sackman as his founding partners in the immersive therapeutics company.

David Sackman is a co-founder and founding chairman of AppliedVR. After leading LRW and Material, he became CEO of Bovitz in 2025. AppliedVR's own founding narrative identifies him alongside Matthew Stoudt and Josh Sackman.

Emily Judge is Vice President of Access and Partnerships at AppliedVR, developing partnerships for its market access and commercial strategies.

Katherine Jackman is senior investment manager at Brandon Capital. She joined in2016 after experimental-stroke research at Weill Cornell and the Florey Institute. Her research investigated progranulin deficiency, cerebral vessels and stroke susceptibility, connecting neurodegeneration research with life-sciences investing. Existing NRG issuer affiliation remains intact. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Saoussen Ben Halima joined Omega in Geneva in 2022 and is a Principal. She previously worked at Roche and Medicxi. Her scientific training includes a neuroscience doctorate at ETH Zurich and Alzheimer disease research at the University of Zurich, with earlier studies at ENS and McGill.

Hakan Goker is a TRIMTECH non-executive director and M Ventures biotechnology managing director. He previously invested at Aescap Venture and Atlas Venture. His scientific training includes oncology research at the Institute of Cancer Research and postdoctoral work at the Royal Marsden; he is based in Amsterdam.

Jonathan Savidge, registered as Jonathan Rex Savidge, is an active statutory director of Acionna Therapeutics Ltd, appointed April24,2025. His Companies House appointment history also identifies NRG Therapeutics; board affiliations do not imply company employment.

Claudio Nessi is named on Anaconda Biomed’s current public board of directors. The issuer identifies the affiliation as OMEGAFUNDS-NeoMed. This confirms the board relationship without establishing a personal investment. Claudio Nessi joined Omega as a Managing Director in 2016 and serves on its investment committee. He previously became a partner at NeoMed after joining in 2001 and worked at Genevest. His scientific career included Max Planck and University of Connecticut research; he holds a Pavia doctorate and an Erasmus MBA.

Charlotte Kremers is Principal at M Ventures. Biotechnology principal who entered the programme as a fellow in2022. Holds Utrecht biology/physiology/neuroscience BSc and UCL neuroscience MSc/PhD, with doctoral research into juvenile ALS mechanisms. Current Principal directory title supersedes older Associate narrative; existing NRG board affiliation preserved.

Francesco Draetta became an Omega Managing Director and investment-committee member in 2023. He first worked at Omega from 2008 to 2012 and returned in 2016 after roles at Brookside and Commonfund. His qualifications include CFA, CAIA and FRM credentials.

Vaccine Company protein and virus sciences director, according to the Peter Kim Lab alumni directory; previously trained as a graduate student in the laboratory.

Vaccine Company protein sciences director, according to the Peter Kim Lab alumni directory; previously a Stanford postdoctoral scholar.

First chief executive and a former board director of Vaccine Company; previously led Merck Global Vaccines.

Vaccine Company chief medical officer in its 2024 filing and principal investigator for its ARPA-H A-FAVE flavivirus vaccine project. Previously worked at the NIH Vaccine Research Center.

Named chief financial officer in Vaccine Company’s California statement of information filed June 14, 2024.

Led Vaccine Company before its acquisition by Eli Lilly; previously held global vaccine and emerging-markets leadership roles at Pfizer.

Venrock healthcare partner and board director of SciThera, with prior biotechnology business development and commercial experience at Clovis Oncology.

Founder and chief executive of SciThera; previously co-founded Inhibrx and served as its chief scientific officer.

Stanford biomedical data science associate professor researching reliable AI for health and disease, formerly at Microsoft Research.

Genomic diagnostics scientist and chief scientific officer at Droplet Biosciences; previously held scientific leadership roles at Glympse Bio, Novartis and the Broad Institute.

UCSF clinical informatics assistant professor researching AI, digital diagnostics and health monitoring.

Data science, statistics and bioinformatics specialist, formerly senior vice president of R&D at Natera.

Computational biology and AI scientist; CTO at Kimia Therapeutics, formerly at Recursion and Freenome.

Scientific executive at Eigen Bio with former discovery research roles at Veracyte and Guardant Health; specializes in AI and genomics.

Genomic diagnostics researcher and R&D executive at Fellow; formerly held product development roles at CareDx and Exact Sciences.

Stanford professor and biomedical informatics and healthcare AI researcher; co-founder of Personalis. Russ Altman, MD, PhD, is a Stanford professor of bioengineering, genetics, medicine and biomedical data science and a senior fellow at the Stanford Institute for Human-Centered Artificial Intelligence. Weave Bio appointed him to its inaugural Strategic Advisory Board inMarch2026. His advisory role supports responsible AI in regulatory science.

Chief of Hepatology and Willis C. Maddrey, M.D. Distinguished Chair in Liver Disease at UT Southwestern Medical Center with 400+ publications over his 25+ year clinical career.

Leland T. Edwards Professor in the School of Engineering at Stanford University with 300+ publications and 70+ issued or pending patents over his 30+ year academic career.

Founding Scientist and Senior Site Director at Counsyl, where he led the automation, delivery, and scaling of advanced blood tests for prenatal screening and hereditary cancer screening.

Former Head of Product and Program Management at GRAIL, where she led strategy for a multi-cancer early detection blood test, after leadership roles at Natera, Progyny, and Sienna Biopharmaceuticals.

Previously Head of R&D at Natera and Head of R&D at GRAIL, where he led the development of advanced blood tests for oncology, prenatal screening, and hereditary cancer screening.

Formerly in Business Development at Genentech, where he led partnership efforts in AI-enabled testing, trials, and therapeutics. Expert in AI, data engineering, and patient monitoring.

Max Klement is a Partner at Novo Holdings Venture Investments, based in London. Max joined Venture Investments in 2022 and is based in the London office. Previously, Max was a Principal at BGV, a life science venture capital firm specialized in early stage companies, where he focused on investments in Europe, the United States, and led multiple company creation initiatives. Max served on the Board of Directors of Complement Therapeutics and was an observer on the Board of Directors of Dualyx, Link Immunotherapeutics, and VarmX. Prior to BGV, he worked in various operational roles at Eden Biologics, a biologics CDMO, and at Hummingbird Bioscience, a company leveraging systems biology for antibody discovery and development. Max studied protein engineering for applications in regenerative medicine as an A*STAR fellow. He holds a PhD in Chemical and Biomolecular Engineering from the National University of Singapore, a BS in Biochemical Engineering from the University of California Irvine, and a Master’s in Business Administration from INSEAD.

Maha Katabi is a General Partner of Sofinnova Investments.

Rogier is a general Partner at Forbion.

Lawrence M.

With over 25 years of experience in antibody discovery and development, he has played a key role in advancing therapeutic candidates in oncology, immunology, and infectious diseases.

A highly accomplished medicinal chemist, she brings over 20 years of experience in drug discovery and development in oncology and virology.

A seasoned cancer biologist and drug discovery leader, he brings over 20 years of experience in oncology research, with a focus on precision medicine and translational science.

With over 25 years of experience in the pharmaceutical industry, he brings deep expertise at the intersection of data science, bioengineering, and technology-driven drug discovery.

Fabrice A.

Gert De Beckker is a biopharmaceutical executive with more than 25 years of experience in global regulatory affairs and drug development.

Tom Govaerts is a senior CMC Leader / Senior Director and brings over 25 years of experience in the pharmaceutical industry.

Lieve is a senior nonclinical safety leader with more than 30 years of experience across global pharma and biotech.

John-Paul Gallivan, currently serves as our Head of Development at Coultreon Biopharma and has over 15 years of experience in the biotech and pharmaceutical industry.

Guy Peeters has over 20 years of experience in finance leadership within the pharmaceutical and biotech sectors.

A seasoned legal executive with over 15 years of experience in the biotech and pharmaceutical industries, she brings deep expertise in R&D collaborations, business development, and strategic transactions.

Nate Massari brings more than 25 years of experience across business development, strategy, and commercialization in the biopharmaceutical industry.

Dr.

Coultreon Biopharma co-founder, CEO, chief scientific officer and board member. Drug discovery executive with former leadership roles at Galapagos, Aligos Therapeutics and Janssen.

Peter DiLaura serves on Character Biosciences’ board; the company lists their affiliation as Independent.

Vivek Garipalli serves on Character Biosciences’ board; the company lists their affiliation as Clover Health. Vivek Garipalli is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Founder & Board Member, Clover Health; that title is context, not an executive position at Thyme Care.

Mayssa Attar serves on Character Biosciences’ board; the company lists their affiliation as Bausch + Lomb.

Reut Shema serves on Character Biosciences’ board; the company lists their affiliation as aMoon. Reut Shema is published by aMoon as Partner. Scientist whose research experience includes Harvard, MIT and the Weizmann Institute; joined in2018 and also works on the Edge public-equity strategy.

Marcel van der Brug is published by Character Biosciences as Scientific Advisor, Co-Founder.

Zachary Katz is published by Character Biosciences as Director, Strategic Initiatives & Alliance Management.

Yunju Yang is published by Character Biosciences as Human Genetics Lead.

Wendy Lin is published by Character Biosciences as Associate Director, Clinical Operations and Clinical Science.

Tejasveeta Nadkarni is published by Character Biosciences as Associate Scientist.

Sumra Farooq is published by Character Biosciences as Clinical Data Manager.

Ryan Campbell is published by Character Biosciences as Senior Research Associate.

Robert Kim is published by Character Biosciences as Chief Medical Officer.

Nathaniel Mooi is published by Character Biosciences as Senior Research Associate.

May Chen is published by Character Biosciences as Director, Drug Discovery.

Maria Avrutsky is published by Character Biosciences as Senior Scientist.

Laura Macri is published by Character Biosciences as Associate Director, Study Operations.

Kaila Smilen is published by Character Biosciences as VP, Corporate Development.

Julia Myers is published by Character Biosciences as Senior Research Associate.

Josh Buddle is published by Character Biosciences as Head of Clinical Network and Longitudinal Research.

Jessamyn Wead is published by Character Biosciences as Head of People.

Jasmin Bharadiya is published by Character Biosciences as Senior Data Engineer.

Isabel Varela is published by Character Biosciences as Operations Analyst.

Geraldine Taveras is published by Character Biosciences as Senior Clinical Research Coordinator.

Erik Karrer is published by Character Biosciences as SVP, Drug Discovery.

Dylan Henry is published by Character Biosciences as Contracts Manager.

Dinah Chen is published by Character Biosciences as Medical Director and Clinical Innovation Lead.

David Buchholz is published by Character Biosciences as Senior Scientist.

Danielle Clark is published by Character Biosciences as Scientist.

Daniel Elgort is published by Character Biosciences as Chief Data and Analytics Officer.

Cheng Zhang is published by Character Biosciences as CEO, Co-Founder.

Brendan Curran is published by Character Biosciences as Engineering Lead.

Andrea Neeranjan is published by Character Biosciences as Associate Director, Clinical Research.

Adria Frazier is published by Character Biosciences as Senior Research Associate.

Aakriti Singh is a research associate at Character Biosciences. This identity is distinct from the TDK Ventures investor of the same name.

Ken Drazan is ArsenalBio’s co-founder, chairman and chief executive officer, as confirmed in its August 2026 strategy announcement.

Genomics and bioengineering researcher at Altos Labs studying cellular health using genome technologies, epigenomics and single-cell sequencing; previously chaired bioengineering at the University of California, San Diego.